Seagen

Youtube Subscribe

Open: 228.74 Close: 228.74 Change: 0.0

Stop waiting time to find out about Seagen Company Inc: Our AI summarizes all info about it.

The game is changing. There is a new strategy to evaluate Seagen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Pfizer, acquisition, deal, cancer, share, Stock, and the …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Pfizer to close $43 billion seagen acquisition this week - marketwatch.com.com. Pfizer expects to close the acquisition of Seagen on December 14. The European Union cleared the transaction in October. The Federal Trade Commission twice asked Pfizer and Seagen for more information on the merger.

Today's News

Pfizers $43b buyout of adc specialist seagen is a done deal. Pfizer anticipates products gained from the Seagen buyout will account for $3.1 billion in revenue in 2024. The Federal Trade Commission twice asked Pfizer and Seagen for more information on the merger. Pfizer expects to close the acquisition of Seagen on December 14. Pfizer is raising the cancer ante after the deadline for the Federal Trade Commission to oppose the Seagen deal expired Monday. The European Union cleared the transaction in October. Pfizer Completes Acquisition of Seagen. EU Antitrust Regulators clear Pfizers $43B Seagen Buy Clears Regulatory Hurdles, Plans Dec 14 Closing. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. Pfizer and Seagen have now received all required regulatory approvals, Pfizer said in a news release that reported a key US antitrust. Pfizer ( NYSE: PFE ) said Tuesday it will close the previously announced agreement to acquire the cancer drugmaker Seagen ( NASDAQ: SGEN ) In March, the New York-based pharma giant offered $229 in cash per share to acquire Seagen in a deal valued at $43B. Pfizer to close $43 billion seagen acquisition this week - marketwatch.com. Pfizer has won all regulatory approvals for its $43B acquisition of biotech cancer specialist Seagen and expects to seal the deal on Thursday. Seagen Inc. (SGEN) Stock , TAK Stock , Seagen (Sgen) Stock, TAK (TAK) Stock. Adcetris (brentuximab vedotin) plus PD-1 inhibitor nivolumab and standard chemotherapy agents. Pfizer announced on Tuesday its anticipation to conclude the $43 billion acquisition of cancer drugmaker Seagen later this week. The pharmaceutical giant revealed plans to establish a new oncology division, incorporating Seagen, in early 2024. Pfizer shares fell sharply on Wednesday after it projected lower-than-expected 2024 profits. Pfizer completes $43 billion acquisition of Seagen - european pharmaceutical manufacturer. Pfizer completed its acquisition of all outstanding common stock of Seagens for $229 in cash per share. Pfizers Oncology pipeline has doubled in size with 60 programs spanning multiple modalities. Pfiziz will leverage its leading protein engineering and medicinal chemistry.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

This document will help you to evaluate Seagen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Pfizer, acquisition, deal, cancer, share, Stock, and the most common words in the summary are: seagen, pfizer, news, job, market, cancer, best, . One of the sentences in the summary was: The European Union cleared the transaction in October. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #pfizer #news #job #market #cancer #best.

Read more →

Youtube Subscribe

---